Skip to content

People with HIV express high satisfaction with monthly injectable regimen

Miranda Murray from ViiV Healthcare presenting the ATLAS study at IAS 2019. Photo by Liz Highleyman.

HIV capsid inhibitor may offer long-term viral suppression

Jennifer Sager presenting at CROI 2019. Photo by Liz Highleyman.

Long-acting injectable treatment maintains viral suppression

Susan Swindells and Chloe Orkin presenting at CROI 2019. Photo by Liz Highleyman.

Removable PrEP implant produces high drug levels in rabbits; further studies planned

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

Zvi Cohen at HIV Glasgow 2018. Image credit: HIV Glasgow

Beyond Truvada – what is the future of PrEP?

Raphael Landovitz at HIVR4P 2018. Photo by Roger Pebody.

First large HIV prevention trial using antibodies will probably not be the last

Lynn Morris at HIVR4P 2018. Photo by Gus Cairns.

The long tail of injectable PrEP is especially long for women

Image from Raphael Landovitz's slides at HIVR4P 2018.

Wide range of views about switching to weekly, monthly or biannual ART